Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Clonal evolution of medulloblastoma brain tumour initiating cells in response to therapy.
FY 2015-16
Summary
Medulloblastoma is the most common type of brain cancer that affects children. Out of the four distinguished subgroups of medulloblastoma, tumours in Groups 3 and 4 are the most aggressive and are associated with a low overall survival in children diagnosed with this type of brain cancer. Recent studies conducted by Dr. Sheila Singh, have shown the existence of few cells within the tumour that alone can drive tumour growth, due to deregulation of genes involved in cell replication. Thus, further studies that will focus on understanding the significance of genes that regulate cell growth and replication can help discover a population of cells that are capable of evading therapy and contribute to tumour relapse. Furthermore, the identification of such population can lead to development of novel treatments for the children affected with aggressive medulloblastoma. In my study, I will initially examine the effects of both increasing and decreasing the activity of genes responsible for cell replication in cells grown in the dish, after which the most promising results will be verified in the established mouse model. The main objective of the proposed study is to discover new opportunities in treatments of most aggressive type of brain cancer affecting children, and thus not only improve the quality of treatment received by the children but also the overall survival of patients with medulloblastoma.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
348002
Name
Bakhshinyan David
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Clonal evolution of medulloblastoma brain tumour initiating cells in response to therapy.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Brain Tumour Initiating Cell; Cancer Stem Cells; Clonal Evolution; Human-Mouse Xenograft; Medulloblastoma; Multimodal Therapy; Neural Stem Cells; Oncogenes; Treatment-Refractory Population; Tumour Relapse
Abstract
Medulloblastoma is the most common type of brain cancer that affects children. Out of the four distinguished subgroups of medulloblastoma, tumours in Groups 3 and 4 are the most aggressive and are associated with a low overall survival in children diagnosed with this type of brain cancer. Recent studies conducted by Dr. Sheila Singh, have shown the existence of few cells within the tumour that alone can drive tumour growth, due to deregulation of genes involved in cell replication. Thus, further studies that will focus on understanding the significance of genes that regulate cell growth and replication can help discover a population of cells that are capable of evading therapy and contribute to tumour relapse. Furthermore, the identification of such population can lead to development of novel treatments for the children affected with aggressive medulloblastoma. In my study, I will initially examine the effects of both increasing and decreasing the activity of genes responsible for cell replication in cells grown in the dish, after which the most promising results will be verified in the established mouse model. The main objective of the proposed study is to discover new opportunities in treatments of most aggressive type of brain cancer affecting children, and thus not only improve the quality of treatment received by the children but also the overall survival of patients with medulloblastoma.
Competitiondate
201510
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bakhshinyan, David
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~